Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prime Medicine, Inc. - Common Stock (NQ:PRME)

2.975 -0.495 (-14.27%)
Streaming Delayed Price Updated: 2:32 PM EDT, Jun 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prime Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
2 Magnificent Growth Stocks With Room to Run ↗
These deeply undervalued growth stocks could be big winners for patient shareholders. 
Via The Motley Fool
News headline image
Short-Squeeze Roulette: 3 Stocks That Could Leave Bears Begging ↗
Explore short-squeeze stocks for potential surges, spotlighting investor strategies and trends that could benefit your portfolio. 
Via InvestorPlace
News headline image
Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too? ↗
On the leading edge of rare disease treatment and therapy is where you will find these Cathie Wood biotech stocks. 
Via InvestorPlace
News headline image
Recap: Prime Medicine Q4 Earnings ↗
 
Via Benzinga
News headline image
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Participate in Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces Pricing of Upsized Public Offering
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Announces Proposed Public Offering of Common Stock
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
2 gene editing stocks to keep on your 2024 watchlist
Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) 
Via MarketBeat
News headline image
Morgan Stanley Reports Q4 Results, Joins Boeing, Alcoa And Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones index falling more than 250 points on Tuesday. 
Via Benzinga
Topics Stocks
News headline image
Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. 
Via Benzinga
News headline image
Better Growth Stock: Archer Aviation or Prime Medicine? ↗
Which of these innovation-themed growth stocks is the better buy? 
Via The Motley Fool
News headline image
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. ↗
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach. 
Via The Motley Fool
News headline image
1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 Years ↗
This gene-editing company could sport a best-in-class platform. 
Via The Motley Fool
News headline image
Prime Medicine to Present at Upcoming Investor Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Ryanair Holdings, Prime Medicine And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
News headline image
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge... 
Via Benzinga
News headline image
DISH Network, Goodyear And 3 Stocks To Watch Heading Into Monday ↗
With U.S. stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
News headline image
Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
7 Biotech Stocks to Get In Now Before Investors Catch On ↗
Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them. 
Via InvestorPlace
News headline image
Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences
From Prime Medicine, Inc.
Via GlobeNewswire
News headline image
Preclinical-Phase Firm Prime Medicine's Gene Editing Platform Has Potential: Analyst ↗
BMO Capital Markets has initiated coverage on Prime Medicine Inc (NASDAQ: PRME), a preclinical-stage company focused on developing therapies based on prime editing. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 9, 2023 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.